A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis
Proceedings of the National Academy of Sciences · 23.05.2023 · 120 (21)
DOI: 10.1073/pnas.2304081120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 15.05.2023. Verfasst von Ji Hyeon Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Korea University, Seoul 02841, Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Prodrugs. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Korea Health Industry Development Institute, National Research Foundation of Korea.
Abstract (Originalsprache)
Chemotherapy typically destroys the tumor mass but rarely eradicates the cancer stem cells (CSCs) that can drive metastatic recurrence. A key current challenge is finding ways to eradicate CSCs and suppress their characteristics. Here, we report a prodrug, Nic-A , created by combining a carbonic anhydrase IX (CAIX) inhibitor, acetazolamide, with a signal transducer and transcriptional activator 3 (STAT3) inhibitor, niclosamide. Nic-A was designed to target triple-negative breast cancer (TNBC) CSCs and was found to inhibit both proliferating TNBC cells and CSCs via STAT3 dysregulation and suppression of CSC-like properties. Its use leads to a decrease in aldehyde dehydrogenase 1 activity, CD44 high /CD24 low stem-like subpopulations, and tumor spheroid-forming ability. TNBC xenograft tumors treated with Nic-A exhibited decreased angiogenesis and tumor growth, as well as decreased Ki-67 expression and increased apoptosis. In addition, distant metastases were suppressed in TNBC allografts derived from a CSC-enriched population. This study thus highlights a potential strategy for addressing CSC-based cancer recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Korea University, Seoul 02841, Korea.
- Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 02841, Korea.
- Brain Korea 21 Program for Biomedical Science, Korea University College of Medicine, Korea University, Seoul 02841, Korea.
- Department of Biomedical Research Center, Korea University Guro Hospital, Korea University, Seoul 08308, Korea.
- Department of Chemistry, The University of Texas at Austin, Austin, TX 78712-1224.
ORCID-Profile: Jonathan L Sessler, Jong Seung Kim
Förderung
- NCI NIH HHS
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Welch Foundation
- HHS | National Institutes of Health
Zitieren
APA
Kim, J. H., Park, S., Jung, E., Shin, J., Kim, Y. J., Kim, J. Y., Sessler, J. L., Seo, J. H., & Kim, J. S. (2023). A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis. Proceedings of the National Academy of Sciences, 120(21). https://doi.org/10.1073/pnas.2304081120
Vancouver
Kim JH, Park S, Jung E, Shin J, Kim YJ, Kim JY, et al. A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis. Proceedings of the National Academy of Sciences. 2023;120(21). doi:10.1073/pnas.2304081120
BibTeX
@article{Kim2023,
author = {Kim, Ji Hyeon and Park, Soeun and Jung, Eunsun and Shin, Jinwoo and Kim, Yoon-Jae and Kim, Ji Young and Sessler, Jonathan L and Seo, Jae Hong and Kim, Jong Seung},
title = {A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {21},
doi = {10.1073/pnas.2304081120}
}
EUVIMED